Fully Licensed with Health Canada, Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) Operates the World’s Largest EU-GMP Compliant Psilocybin Cultivation Facility

If you think for one second that the psychedelic movement taking place right now is just “hype,” think again.

Why?

Because, unlike the psychedelic movement of the 60s, which conjures up images of tie-dye T-shirts and peace signs, the current psychedelic renaissance is fueled by science, governments, celebrities and big-time investors.

From Time magazine founder Henry Luce1 to entertainers like Sting2 and Kristen Bell3 to elite athletes like boxer Mike Tyson4 and former NHL star Mark Messier,5 and even one of the NFL’s top quarterbacks, Aaron Rodgers,6 celebrities and prominent influencers are touting the many benefits of psychedelics.

Even streaming giant Netflix continuously features psychedelic documentaries that further push the idea of psychedelics as medicine into the mainstream.

And the latest documentary, “How to Change Your Mind” by best-selling author and journalist Michael Pollan has effectively tipped the scales in favor of psychedelics.7

Gone are the days when magic mushrooms and MDMA were merelyy party drugs with a bad rep.

Their potential to save lives is so evident that even President Joe Biden expected regulators to approve MDMA and psilocybin within the next two years to treat PTSD and depression.8

And smart investors are quickly catching onto the massive potential of this market.

Just look at the recent trading volume of stocks in the space. Like Mind Medicine, which experienced over 160 million in one day and shot up almost 50%.

Even one of the world’s best trend spotters, Chip Wilson,9 10 founder of athleisure juggernaut Lululemon Athletica (NASDAQ:LULU) (market cap +US$40 billion), has turned his attention towards psychedelics.11

But instead of following the hype surrounding stocks like MindMed (which may have been created by a 20-year-old USC student5), Wilson has uncovered a hidden gem that the rest of the market hasn’t caught wind of yet.

That company is called Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF).

Built to provide the backbone for psychedelic medicine developers in the West with the world’s largest EU-GMP compliant psilocybin cultivation facility is Optimi Health Corp.  

OPTI is already fully licensed with Health Canada and backed by a billionaire trend spotter who’s about to score another win.

Optimi Health Corp. not only operates the world’s largest EU-GMP compliant psilocybin cultivation facility but it’s also built to supply ALL other companies that want to get into the psilocybin space.

Why is psilocybin such a big deal? Well, science has just revealed that in the long run, SSRIs (mainstream antidepressants) do practically nothing to improve patients’ lives.13,14

Yet, psilocybin is showing promising results for treating depression, along with other mental health issues like anorexia,15 anxiety,16 cluster headaches,17 and obsessive-compulsive disorder.18

These magic mushrooms have been hitting nothing but home runs, showing effectiveness in major depression for up to a year for most patients.12

They work… and they work well.

Functional mushrooms like lion’s mane and cordyceps are also gaining a following for their potential health benefits and are fully legal across the globe.

This is another bonus for Optimi Health Corp., which already has a line of functional mushroom products on the market and is gaining revenue.

By now, it should be evident to you that an exciting new trend is upon us.

When Chip Wilson saw yoga on the rise, did he invest in a chain of yoga studios? Heck no.

He went for the proverbial picks and shovels play by outfitting the flocking crowd.

Today, Lululemon has nearly 600 stores around the world20 and is pulling in over $6.3 billion annually.21

When you look at how profitable that venture was and still is, it’s easy to see why investors should pay attention to this man.

Like Lululemon, Optimi Health Corp. another picks-and-shovels play that stands out. Optimi is a fully vertically integrated cultivation to consumer business meaning the company controls the entire supply chain.

Now, let’s break down the numerous reasons why Optimi Health is easily THE BEST WAY to get in on the wild world of magic mushrooms, as the functional fungi is poised to take the mental health industry by storm.

7 Reasons Optimi Health (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) is a Primary Driver in the Mushroom Revolution

  1. Fully Licensed by Health Canada: To date, Health Canada has only licensed 22 entities to produce psilocybin and synthetic psychedelic products, only a handful of which have the ability to actually supply the market. Optimi Health Corp. is approved to supply Canada’s Special Access Program (SAP) as well as Clinical Trials and is fully licensed to package and export products globally, with the know-how of its in-house distribution experts.
  2. Full Vertical Integration / Cultivation to Consumer (CTC): Stacked with multi-revenue generating assets such as e-Commerce, farm, and lab facilities, Optimi Health is built for success, having already established international sales and growth opportunities with B2B relationships. This means that Optimi, which is ready to deliver products to patients, is the one-stop shop for ANY big psilocybin company looking to get products to market. If they want the ingredients, chances are highly likely they’ll need to go through Optimi to obtain them.
  1. Largest EU-GMP compliant Psilocybin Cultivation Facility in the World: Already equipped with in-house Health Canada consulting, Optimi Health received its Health Canada Research Exemption in Jan 2021. The company later submitted for its Health Canada Dealers License Application for large-scale psilocybin cultivation at its TWO 10,000 sq ft GMP & EU GMP-capable facilities that house one of the sector’s largest genetic strains banks of psilocybin and functional mushrooms. OPTI has just received permission from Health Canada to manufacture and distribute other psychedelic substances, most notably MDMA.22 The company also has room to expand, with +25 acres permitted and zoned for use to grow with increased market demand and regulation.
  2. Well-Funded Revenue Runway: Through a very successful oversubscribed IPO, Optimi collected $20.7 million, that’s earmarked for financial investments that encompass the company’s capital expenditures for facilities, licensing, eCommerce platform buildout, strategic acquisitions, G&A, and other working capital. All the while, the company has prudently remained debt-free to date. Not to mention its large insider positions (which keep growing) and buying in the market.
  3. Series of Supply Agreements and Partnerships: Not wasting any time, Optimi has amassed a string of deals, including supply agreements with Calgary-based Bloom Psychedelic Therapy and Research Centre23  and SABI Mind, a clinic group providing psychedelic-assisted therapies.24 The company is also preparing to supply many clinical trials around the world.
  4. Steady Stream of R&D: Doing its part to move the entire sector ahead, Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) has partnered up with multiple groups to advance R&D in the space, including signing an agreement with a University of Calgary incubator for review, design, planning and/or conducting clinical trial studies for future Optimi products; and applying for a second provisional patent for a unique proprietary two-part extraction and transdermal delivery process.
  5. Exceptional Leadership with Strong Track Record of Success: Among its many professionals leading the way for Optimi, the most notable figure is billionaire founder of Lululemon (mkt cap $40B) sits on the advisory board.

Optimi: The Company Built to Supply All Other Psychedelic Players in the Space

Governments around the world are starting to embrace psychedelics, including in the United States, where President Joe Biden’s administration anticipates regulators will approve treatments involving MDMA and psilocybin25 within the next two years as designated breakthrough therapies for PTSD and Depression.26

To the North, Canada has already begun to approve psychedelics for treatment, which medical experts see as a very positive step.27

All this means that there’s likely going to be a flood into the North American psilocybin space very soon, and the ones who already are established ahead of time will flourish.

With its world-class facility that’s up-to-code for internationally recognized standards and an in-house team specialized in global trade compliance, Optimi Health Corp. is perfectly positioned to capitalize on this obviously-set-to-explode market.

In fact, Optimi has the unique opportunity to supply ALL of the major psychedelics companies in the market—meaning: THIS COMPANY HAS NO TRUE COMPETITION.

By simply looking at its credentials, there’s no other company that can compare with the potential of Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF).

  • Fully licensed by Health Canada
  • Well-funded revenue pathway
  • The world’s LARGEST EU-GMP compliant psilocybin cultivation facility
  • Fully vertically integrated operation, built for cultivation to consumer (CTC)

While the market is clearly starting to give noticeable values to other companies in the psychedelic medicine space, Optimi is supplying natural, EU-GMP psilocybin and synthetic psychedelics that ALL of the companies listed below would benefit from while conducting their own research in this fast-growing field.

To put it another way, if we were talking about the electric vehicles (EV) industry, Optimi would be the world’s largest lithium producer and in a position to supply all of the lithium batteries for the entire EV market.

“I think, generally, people should be open to psychedelics… A lot of people making laws are kind of from a different era, so I think, as the new generation gets into political power, I think we will see greater receptivity to the benefits of psychedelics.”37 

Elon Musk, the World’s Richest Man

Targeting a MASSIVE Mental Health Market Opportunity

As can be seen in the chart above, while some of the large companies have been approved by regulators for trials, only Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) is licensed to PRODUCE & DISTRIBUTE psilocybin in large-scale quantities for eventual commercial sales.

In order to continue their research, and to move forward toward the launch of new products, most of these industry giants will need a tier 1 ingredients supplier such as Optimi to fulfill their supply needs, and to bring their drugs or formulations to market.

New investment is flooding into this space, attracting significant interest from the Venture Capitalist community.

While in 2016, only 12 VC transactions were conducted in the psychedelic space…, in 2021, that number nearly expanded FIVE-FOLD to 56.[138

For Optimi Health, the market opportunity goes FAR BEYOND just supplying others with medicinal ingredients.

Not only does Optimi’s opportunity involve cultivation, but the entire operation includes a very strong business model and a Vertically Integrated Operation that extends from Cultivation to Consumer (CTC), offering multiple revenue streams along the way.

Optimi Health’s potential multi-revenue generating assets include:

  • E-Commerce
  • Farm and Lab Facilities
  • International sales and growth opportunities established through B2B relationships (more on this below!)

Important Market Statistics and Projections

The overall Global Mental Health Market is projected to skyrocket to more than US$527 billion by 2030.39

The Global PTSD Treatment Market is valued at US$990.7 million, and projected to grow at a CAGR of 4.2% through to 2028.40

The Market for Treating Anxiety Disorders and Depression is set to grow to US$13 billion by 2027.41

The Global Psychedelics Drugs Market is projected to reach US$6.4 billion by 2029.42

The Largest, EU-GMP Compliant Psilocybin Cultivation Facility in the World

As we’ve already highlighted above, Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) has the world’s largest EU-GMP compliant psilocybin cultivation facility, which is integral to the company’s story.

What exactly does this mean? Is bigger automatically better?

Well, in this case… YES. It is.

The first facility, Optimi Developmental, was designed as the first state-of-the-art pharmaceutical-grade operation and future global leading GMP certified producer and supplier of psilocybin mushrooms for the ever-growing psychedelic research and pharmaceutical industry.

The next facility, Optimi Functional, was designed specifically for CTC (Cultivation To Consumer), with an aim towards maximizing margin across the value chain with on-site extraction capabilities, new product innovation, packaging and ground-up production of high-demand functional mushroom varieties such as Lion’s Mane, Reishi, Turkey Tail, and Cordyceps.

Together, these make Optimi Health an absolute POWERHOUSE in the psilocybin & psychedelics industry. In February 2022, the company was approved for large-scale psilocybin cultivation, and on August 5th Optimi was granted  further approval by Health Canada to manufacture and distribute MDMA and other synthetic psychedelics.43

At its core, perhaps the biggest asset besides the brick and mortar infrastructure is the IP, as Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) has amassed one of the world’s largest genetic strain banks of psilocybin and functional mushrooms in the sector.44

Functional Mushroom Products = Additional, Fully-Legal Revenue Stream

While much of the talk so far has been around the potential for soon-to-be-legal psychedelic therapy products, there’s another important piece to the Optimi Health puzzle—functional mushroom products that are ALREADY legal.

Optimi Health currently produces and sells a line of functional mushroom products, which fall under the rapidly growing market of nutraceuticals—foods containing health-giving additives and having medicinal benefits.

The Global Nutraceuticals Market is predicted to hit US$516.5 billion by 2028, growing at a CAGR of 7.6% along the way.45

Within that group, the Global Functional Mushroom Market had a value of US$27.7 billion in 2021, and is expected to grow by a CAGR of 8.44% to US$52.3 billion by 2030.46

By tapping into this market, OPTI is targeting more than just patients of therapists, but also the over-the-counter, wellness-seeking crowd. These products are legal all around the world and are becoming increasingly more and more popular.

Having the ability to generate revenue from functional mushroom products further separates Optimi Health from its solely-research-focused psychedelic medicine company counterparts.

Well-Funded Revenue Pathway with a STRONG Business Model

Excitement surrounding the potential for Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) has been red hot from the moment it started trading.

Early in 2021, in its Initial Public Offering (IPO), OPTI raised $20.7 million through an oversubscribed financing driven by co-founder JJ Wilson and his billionaire father, who’s famous for spotting huge trends before they explode.47

Since then, Optimi Health Corp. has gone on to build upon this momentum more, by taking on many millions of dollars’ worth of orders—with a constant stream of new deals being announced all the time.

When looking at all that Optimi has delivered on from their prospectus over the last year and a half, this company has been hitting it out of the park.

Recent key catalysts include: Facilities (complete), First Grow (complete), First Sale (complete), First batch of psilocybin with the next batch at the end of August (already sold), and an Analytical Laboratory (complete). The company is currently growing one of the largest legal psilocybin harvests ever.

Today, Optimi is already generating revenue—all of which was achieved successfully and prudently with NO DEBT, while working towards a very feasible goal of cash neutrality, and eventually positive EBIDTA.

The company achieved this by building out the business on multiple fronts (functional and psilocybin mushrooms).

So far, Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) has amassed and signed a series of significant partnership and supply agreements. Each of these provides more opportunities for liquidity, while simultaneously increasing brand awareness and building up a respectable industry-wide reputation.

Among the more notable deals to date, have been:

  • A supply agreement with clinical-stage natural psychedelic drug development company, Filament Health, for psilocybin mushrooms48
  • An exploratory supply agreement with ATMA Journey Centers, a psilocybin-assisted therapy and practitioner training services facilitator for palliative care and mental health49
  • Consulting services agreement with a University of Calgary business incubator for review, design, planning and/or conducting clinical trial studies for future Optimi
  • A supply agreement with Halucenex Life Sciences, a wholly owned subsidiary of Creso Pharma of Australia50

Exceptional Leadership Team

In order to deliver upon such high expectations in the mushrooms-as-medicine space, Optimi Health is built to succeed with world-class stewardship. Beyond its management team, Optimi’s being guided by incredible advisors, including Edward Safarik who is the former Founder, President and CEO of Ocean Fisheries Limited, celebrity fitness and nutrition specialist Harley Pasternak, and other outstanding minds.

OPTI’s leadership team includes:

William (Bill) J. Ciprick

CEO

Over 25 years of Global experience across a wide array of industries in multifunctional organizations ranging from Fortune 500 corporations to small and medium-sized businesses. Prior experience includes leading a specialty advisory practice for the Business Development Bank of Canada, running his own successful consulting firm and helping a high-tech company go public and grow from $200M to $800M in under 4 years. Ciprick additionally spent 17 years at Procter & Gamble and has a love and proven track record for growing products and brands.

Bryan Safarik

COO & Director

Over 15 years of experience in Senior Management roles, as well as Founder and President of various profitable private companies. His experience includes serving as Director of Marine Operations at Ocean Fisheries LTD before the sale to the Jim Pattison group. Safarik also co-founded, and currently serves as President for BC Green Pharmaceuticals Inc.

Dane Stevens

CMO & Director:

An entrepreneur with 15 years of experience in international product sourcing, development, manufacturing, and quality control, Stevens is the founder of multiple successful wholesale and retail DTC businesses and is currently President of Cavalier Jewellers LTD. After investing in several venture start-ups, he now concentrates his efforts on various philanthropic endeavours, and on the science-based benefits in the rapidly evolving world of fungi.

JJ Wilson

Co-Founder, Chairman of the Board

Active CEO and Co-Founder of Ride Cycle Club and Partner at Very Polite Agency. Wilson’s previous experience includes leading the international expansion of Kit and Ace, in addition to developing the business’s brand, eCommerce, and retail. A recent graduate from Harvard Business School, Wilson now focuses on strategic growth initiatives and development for his operating companies, in addition to independent strategic investments, and philanthropy.

Jacob Safarik

Co-Founder, CFO

Over 15 years of experience in accounting, project finance, business development and quality assurance. Prior experience includes playing a lead advisory role in the divestiture and sale of a $6 billion business in San Francisco. Safarik also worked in Vienna, Austria where he managed various audit and assurance engagements for key infrastructure and development initiatives funded by the European Union. He’s also a Co-Founder and Chief Financial Officer of BC Green Pharmaceuticals Inc.

RECAP: 7 Reasons To Seriously Look Into Optimi Health Corp. (CSE:OPTI)(OTCQX:OPTHF)(CSE:OPTI)(OTCQX:OPTHF) NOW!

  1. Fully Licensed by Health Canada
  2. Full Vertical Integration / Cultivation to Consumer (CTC)
  3. Largest EU-GMP Compliant Psilocybin Cultivation Facility in the World
  4. Well-Funded Revenue Runway
  5. Series of Supply Agreements and Partnerships
  6. Steady Stream of R&D
  7. Exceptional Leadership with Strong Track Record of Success

With so many incredible products under development, the infrastructure and leadership in place to succeed, now is THIS IS THE PERFECT TIME for smart investors to seriously follow the ongoing Optimi story.

OPTI has amassed an impressive portfolio while building out the world’s LARGEST EU-GMP-compliant psilocybin cultivation facility.

This is a bonafide picks-and-shovels play in the rapidly expanding psychedelics space, all while also offering a full vertically integrated CTC business model.

You’re going to want to keep tabs on this future mushroom JUGGERNAUT by clicking here to visit their website and sign up for the company’s newsletter to make sure you don’t miss out on any of Optimi Health’s news and milestones.

1https://www.economist.com/international/2019/06/08/magic-mushrooms-illegal-in-most-places-may-have-therapeutic-uses
2 https://canoe.com/entertainment/celebrity/psychedelic-drugs-can-solve-problems-sting-raves-about-lsd-mushrooms
3 https://people.com/health/kristen-bell-tried-hallucinogenic-mushrooms-to-help-manage-her-depression/
4 https://www.reuters.com/lifestyle/sports/mike-tyson-says-psychedelics-saved-his-life-now-he-hopes-they-can-change-world-2021-05-28/
5 https://www.menshealth.com/health/a37707611/mark-messier-nhl-magic-mushrooms-no-one-wins-alone-book/
6 https://thesportsrush.com/nfl-news-how-aaron-rodgers-magic-mushrooms-and-psychedelics-led-to-his-200-million-contract-extension/
7 https://www.nytimes.com/2022/07/15/arts/television/how-to-change-your-mind-netflix-michael-pollan.html
8 https://www.theguardian.com/science/2021/nov/07/will-the-magic-of-psychadelics-transform-psychiatry
9 https://arts.ucalgary.ca/lrc/news/lululemon-founder-chip-wilson-shares-entrepreneurial-thinking
10 https://www.businessinsider.com/lululemon-chip-wilson-predicts-next-clothing-trend-2018-10
11 https://www.bcbusiness.ca/You-Had-Me-At-IPO-Chip-Wilson-sees-things-with-mushroom-company-Optimi-Health-Corp
12 https://www.marketwatch.com/story/this-investor-made-110-million-from-trading-bed-bath-beyond-and-hes-reportedly-a-20-year-old-student-11660814284?mod=home-page
13 https://www.usnews.com/news/health-news/articles/2022-04-20/in-long-run-antidepressants-dont-improve-quality-of-life-study
14 https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=With%20antidepressants%3A%20About%2040%20to,within%20six%20to%20eight%20weeks
15 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015070/
16 https://www.hopkinsmedicine.org/news/media/releases/hallucinogenic_drug_psilocybin_eases_existential_anxiety_in_people_with_life_threatening_cancer
17 https://ichgcp.net/clinical-trials-registry/NCT02981173
18 https://pubmed.ncbi.nlm.nih.gov/17196053/
19 https://www.hopkinsmedicine.org/news/newsroom/news-releases/psilocybin-treatment-for-major-depression-effective-for-up-to-a-year-for-most-patients-study-shows
20 https://www.statista.com/statistics/564448/retail-stores-forecast-of-lululemon/
21 https://corporate.lululemon.com/media/press-releases/2022/03-29-2022-210531813
22 https://www.optimihealth.ca/health-canada-grants-mdma-production-and-distribution-amendment-to-optimi-health/
23 https://www.optimihealth.ca/optimi-health-finalizes-psilocybin-supply-agreement-with-bloom-psychedelic-therapy-and-research-centre/
24 https://www.optimihealth.ca/optimi-health-initiates-agreement-with-sabi-mind-for-therapeutic-supplies-of-psilocybin-mdma/
25 https://www.optimihealth.ca/biden-administration-plans-for-legal-psychedelic-therapies-within-two-years/
26 https://theintercept.com/2022/07/26/mdma-psilocybin-fda-ptsd/
27 https://globalnews.ca/news/8514429/psychedelic-drugs-therapy-canada/
28 https://www.globenewswire.com/en/news-release/2022/02/16/2386320/0/en/Optimi-Health-Approved-to-Supply-Psilocybin-Under-Health-Canada-s-Special-Access-Program.html
29 https://www.globenewswire.com/en/news-release/2022/05/04/2435756/0/en/Optimi-Health-Granted-Amendment-To-Controlled-Substances-Dealer-s-Licence.html
30 https://www.globenewswire.com/en/news-release/2021/12/21/2356149/0/en/Optimi-Health-Receives-Dealers-License-Inspection-and-Introduces-Quality-Assurance-Department.html
31 https://autos.yahoo.com/autos/optimi-health-requests-approval-manufacture-130000065.html
32 https://www.newswire.ca/news-releases/compass-pathways-receives-fda-approval-for-psilocybin-therapy-clinical-trial-for-treatment-resistant-depression-691452071.html
33 https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-fda-investigational-new-drug-ind 34 https://www.atai.life/2021/03/10/atai-life-sciences-demerx-receives-mhra-approval-for-dmx-1002-ibogaine-to-commence-phase-1-2a-study-as-first-clinical-trial-in-opioid-use-disorder-in-the-uk/
35 https://www.businesswire.com/news/home/20220817005140/en/Cybin-and-Clinilabs-Granted-Schedule-I-DEA-License-for-CYB003-Phase-12a-First-In-Human-Clinical-Trial
36 https://www.prnewswire.com/news-releases/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder-301467114.html
37 https://www.iflscience.com/elon-musk-says-people-should-open-psychedelics-61138
38 https://www.fcf.de/blog/psychedelics-attract-more-vc-investments/
39 https://www.globenewswire.com/en/news-release/2022/06/22/2467263/0/en/Global-Mental-Health-Market-is-estimated-to-be-US-527-44-billion-by-2030-with-a-CAGR-of-3-40-during-the-forecast-period-By-PMI.html
40 https://www.digitaljournal.com/pr/post-traumatic-stress-disorder-treatment-market-was-valued-at-us-990-7-million-in-2021-and-will-grow-with-a-cagr-of-4-2-from-2022-to-2028-allergan-plc-astrazeneca-eily-lilly-and-company-glaxosmi
41 https://www.globenewswire.com/news-release/2022/06/13/2460905/0/en/Anxiety-Disorders-and-Depression-Treatment-Market-Size-worth-USD-13-03-Billion-by-2027-at-CAGR-of-2-6.html
42 https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-market
43 https://www.optimihealth.ca/health-canada-grants-mdma-production-and-distribution-amendment-to-optimi-health/
44 https://www.optimihealth.ca/optimi-health-acquires-extensive-catalog-of-psychedelic-and-functional-mushroom-genetics/
45 https://www.prnewswire.com/news-releases/global-nutraceuticals-market-predicted-to-gather-516-5-billion-by-2028–growing-at-cagr-of-7-60-from-2021-2028-175-pages–says-research-dive-301590755.html
46 https://www.digitaljournal.com/pr/functional-mushroom-market-growing-impressive-business-opportunities-industry-trends-global-demand-future-scope-2022-2028-nammex-hirano-mushroom-llc-mitoku-company-ltd
47 https://www.bcbusiness.ca/You-Had-Me-At-IPO-Chip-Wilson-sees-things-with-mushroom-company-Optimi-Health-Corp#:~:text=Are%20You%20Seeing%20This%3F,scale%20cultivator%20of%20psychedelic%20mushrooms.
48 https://www.optimihealth.ca/optimi-health-enters-into-psilocybin-supply-agreement-with-filament-health/
49 https://www.optimihealth.ca/optimi-health-finalizes-partnership-and-psilocybin-supply-agreement-with-atma-journey-centers/
50 https://www.optimihealth.ca/optimi-health-signs-psilocybin-supply-agreement-with-halucenex-life-sciences-inc/

IMPORTANT NOTICE AND DISCLAIMER

This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Optimi Health Corp. (“OPTI”) and its securities, OPTI has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by OPTI) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP.

The Publisher does not own any shares of any profiled company OPTI and has no information concerning share ownership by others of in the profiled company OPTI. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

FORWARD LOOKING STATEMENTS.

This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to OPTI industry; (b) market opportunity; (c) OPTI business plans and strategies; (d) services that OPTI intends to offer; (e) OPTI milestone projections and targets; (f) OPTI expectations regarding receipt of approval for regulatory applications; (g) OPTI intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) OPTI expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute OPTI business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) OPTI ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) OPTI ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) OPTI ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of OPTI to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) OPTI operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact OPTI business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing OPTI business operations (e) OPTI may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

INDEMNIFICATION/RELEASE OF LIABILITY.

By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

INTELLECTUAL PROPERTY.

Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

IMPORTANT NOTICE AND DISCLAIMER

This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:

  • The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Optimi Health Corp..

SHARE OWNERSHIP

The Website Host does not own any shares of any profiled Optimi Health Corp. and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

NO SECURITIES OFFERED

The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Optimi Health Corp. or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Optimi Health Corp.. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Optimi Health Corp.’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

LINKS TO THIRD PARTY WEBSITES

This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.

INTELLECTUAL PROPERTY

The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.

FORWARD LOOKING INFORMATION

This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Optimi Health Corp. future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Optimi Health Corp. industry; (b) market opportunity; (c) Optimi Health Corp. business plans and strategies; (d) services that Optimi Health Corp. intends to offer; (e) Optimi Health Corp. milestone projections and targets; (f) Optimi Health Corp. expectations regarding receipt of approval for regulatory applications; (g) Optimi Health Corp. intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Optimi Health Corp. expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Optimi Health Corp. business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Optimi Health Corp. ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Optimi Health Corp. ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Optimi Health Corp. ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Optimi Health Corp. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Optimi Health Corp. operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Optimi Health Corp. business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Optimi Health Corp. business operations (e) Optimi Health Corp. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

HISTORICAL INFORMATION

Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Optimi Health Corp. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Optimi Health Corp. or such entities and are not necessarily indicative of future performance of Optimi Health Corp. or such entities.